Government response to 3 medicines reports

This response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines.

Government response to 3 ACMD reports

Details

The government accepts the ACMD's recommendations in relation to the classification and scheduling of the 5 medicines featured in the ACMD's reports:

• Somapacitan, lonapegsomatropin and somatrogon: ACMD advice
• Ganaxolone: ACMD advice
• Zuranolone: ACMD advice

The ACMD recommended that:

• the 3 growth hormones somapacitan, lonapegsomatropin, and somatrogon should be controlled under Class C of the Misuse of Drugs Act 1971 and scheduled under Schedule 4 (Part 2) to the Misuse of Drugs Regulations 2001

• ganaxolone, a neuroactive steroid to treat a rare form of epilepsy, should not be controlled under the Misuse of Drugs Act 1971 nor scheduled under the Misuse of Drugs Regulations 2001 at this time

• zuranolone, an oral, synthetic neuroactive steroid (NAS) with rapid antidepressant effects used to treat post natal depression, should be controlled under Class C of the 1971 Act and scheduled under Schedule 4, (Part I) of the 2001 Regulations